Showing results (291-300 of 523) with videos related to
Sort By:
Pageof 53
Expert Opinion on Biological Therapy|January 31, 2017
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for researchValentina Zambonin, Alessandro De Toma, Luisa Carbognin, et al.Journal of Surgical Oncology|May 6, 2022
Lymphadenectomy for lung carcinoids: Which factors may predict nodal upstaging? A multi centric, retrospective studyMarco Chiappetta, Filippo Lococo, Isabella Sperduti, et al.Biomed Research International|August 9, 2014
Diagnostic features and subtyping of thymoma lymph node metastasesStefano Sioletic, Libero Lauriola, Enzo Gallo, et al.Oncoimmunology|August 17, 2017
IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancerEleonora Timperi, Chiara Focaccetti, Daniela Gallerano, et al.Lung Cancer (Amsterdam, Netherlands)|June 9, 2014
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter studyRossano Lattanzio, Rossana La Sorda, Francesco Facciolo, et al.Cancers|November 13, 2021
Masaoka-Koga and TNM Staging System in Thymic Epithelial Tumors: Prognostic Comparison and the Role of the Number of Involved StructuresMarco Chiappetta, Filippo Lococo, Luca Pogliani, et al.Tomography (Ann Arbor, Mich.)|November 29, 2021
Cryoablation in Locoregional Management of Complex Unresectable Chest NeoplasmsRoberto Iezzi, Andrea Contegiacomo, Alessandro Posa, et al.BMC Cancer|December 15, 2010
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trialsFederica Cuppone, Emilio Bria, Diana Giannarelli, et al.The Lancet. Oncology|November 14, 2024
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysisLuca Mastrantoni, Marta Chiaravalli, Alexia Spring, et al.Cancers|November 14, 2019
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT TrialsValentina Rossi, Paola Berchialla, Diana Giannarelli, et al.Pageof 53